Cabaletta Bio Inc [CABA] stock prices are up 3.31% to $24.32 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CABA shares have gain 7.14% over the last week, with a monthly amount glided 9.16%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Cabaletta Bio to Participate in Upcoming Investor Conferences in March. In a post published today on Yahoo Finance, Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in March:.
From an analyst’s perspective:
Cabaletta Bio Inc [NASDAQ: CABA] stock has seen the most recent analyst activity on February 05, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $36. Previously, William Blair started tracking the stock with Outperform rating on November 29, 2023, and set its price target to $38. On October 24, 2023, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $40 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $31 on October 19, 2023. Citigroup initiated its recommendation with a Buy and recommended $22 as its price target on September 05, 2023. Guggenheim started tracking with a Buy rating for this stock on July 18, 2023, and assigned it a price target of $34. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $3 to $16.
The stock price of Cabaletta Bio Inc [CABA] has been fluctuating between $5.88 and $26.35 over the past year. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Cabaletta Bio Inc [NASDAQ: CABA] shares were valued at $24.32 at the most recent close of the market. An investor can expect a potential drop of -65.05% based on the average CABA price forecast.
Analyzing the CABA fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.75 points at the first support level, and at 23.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.69, and for the 2nd resistance point, it is at 25.06.
Cabaletta Bio Inc [CABA] reported earnings per share of -$0.37 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.4/share, meaning a difference of $0.03 and a surprise factor of 7.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.37 per share as compared to estimates of -$0.44 per share, a difference of $0.07 representing a surprise of 15.90%.
Ratios To Look Out For
It’s worth pointing out that Cabaletta Bio Inc [NASDAQ:CABA]’s Current Ratio is 15.65. On the other hand, the Quick Ratio is 15.65, and the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Binder Gwendolyn,, that happened on Jan 19 when 11000.0 shares were sold., Binder Gwendolyn completed a deal on Dec 19 to sell 11000.0 shares. Meanwhile, Binder Gwendolyn sold 11000.0 shares on Nov 20.
